The stock of Achieve Life Sciences Inc (ACHV) has gone up by 8.79% for the week, with a 22.22% rise in the past month and a -6.31% drop in the past quarter. The volatility ratio for the week is 5.65%, and the volatility levels for the past 30 days are 5.74% for ACHV. The simple moving average for the past 20 days is 11.75% for ACHV’s stock, with a -19.82% simple moving average for the past 200 days.
Is It Worth Investing in Achieve Life Sciences Inc (NASDAQ: ACHV) Right Now?
The 36-month beta value for ACHV is at 1.57. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ACHV is 29.37M, and currently, shorts hold a 8.60% of that float. The average trading volume for ACHV on May 23, 2025 was 199.70K shares.
ACHV) stock’s latest price update
The stock price of Achieve Life Sciences Inc (NASDAQ: ACHV) has dropped by -5.41 compared to previous close of 3.14. Despite this, the company has seen a gain of 8.79% in its stock price over the last five trading days. globenewswire.com reported 2025-05-20 that SEATTLE and VANCOUVER, British Columbia, May 20, 2025 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that additional analyses from its Phase 3 ORCA-3 study will be presented during an oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco, CA. Presentation Details: Title: Cytisinicline Reduces Cravings and Nicotine Intake in People Who Smoke and Don’t Quit Completely Session: C95 – Public Health and Policy Relevant Research Format: Mini Symposium Oral Presentation Date & Time: Tuesday, May 20, 2025; 2:15 PM – 4:15 PM EDT Location: 2025 ATS International Conference The oral presentation will highlight the unique benefit of cytisinicline treatment in clinical trials in reducing nicotine cravings which led to reduced nicotine intake, even in individuals who did not achieve complete smoking cessation.
Analysts’ Opinion of ACHV
Many brokerage firms have already submitted their reports for ACHV stocks, with Rodman & Renshaw repeating the rating for ACHV by listing it as a “Buy.” The predicted price for ACHV in the upcoming period, according to Rodman & Renshaw is $12 based on the research report published on November 14, 2024 of the previous year 2024.
Raymond James, on the other hand, stated in their research note that they expect to see ACHV reach a price target of $20. The rating they have provided for ACHV stocks is “Strong Buy” according to the report published on September 27th, 2024.
Maxim Group gave a rating of “Buy” to ACHV, setting the target price at $20 in the report published on May 10th of the previous year.
ACHV Trading at 16.16% from the 50-Day Moving Average
After a stumble in the market that brought ACHV to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -46.87% of loss for the given period.
Volatility was left at 5.74%, however, over the last 30 days, the volatility rate increased by 5.65%, as shares surge +23.75% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +12.08% upper at present.
During the last 5 trading sessions, ACHV rose by +8.79%, which changed the moving average for the period of 200-days by -33.56% in comparison to the 20-day moving average, which settled at $2.66. In addition, Achieve Life Sciences Inc saw -15.62% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACHV starting from Oki Mark K, who purchase 10,000 shares at the price of $2.89 back on Mar 17 ’25. After this action, Oki Mark K now owns 10,000 shares of Achieve Life Sciences Inc, valued at $28,887 using the latest closing price.
Stewart Richard Alistair, the Chieve Executive Officer of Achieve Life Sciences Inc, purchase 10,000 shares at $2.86 during a trade that took place back on Mar 17 ’25, which means that Stewart Richard Alistair is holding 60,876 shares at $28,598 based on the most recent closing price.
Stock Fundamentals for ACHV
The total capital return value is set at -1.02. Equity return is now at value -154.55, with -94.80 for asset returns.
Based on Achieve Life Sciences Inc (ACHV), the company’s capital structure generated 0.49 points at debt to capital in total, while cash flow to debt ratio is standing at -3.57. The debt to equity ratio resting at 0.97. The interest coverage ratio of the stock is -17.47.
Currently, EBITDA for the company is -37.42 million with net debt to EBITDA at 0.1. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.51.
Conclusion
In conclusion, Achieve Life Sciences Inc (ACHV) has had a mixed performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
